Eurofins Discovery

Metabolic disorders significantly increase the risk for debilitating or life-threatening health conditions. Obesity is a chronic metabolic disease impacting multiple organ systems and increasing the propensity for serious conditions including liver disease, diabetes, and even dementia. Partner with our IDD team to advance your obesity drug development: ✔ Specialized Services: A broad range of target-based and translational assays, with an innovative obesityLITE panel of 25 cell-based assays for 13 obesity-related targets in two key signaling modalities. ✔ Renowned Safety Assays: Rigorously assess safety with SafetyScreen18, a rapid and cost-effective panel of 18 DruSafe recommended off-targets for early identification of potential safety risks.  ✔ Dedicated Solutions: With GPCRs as targets for weight management, tap into the expertise of Eurofins Discovery’s dedicated GPCR group for support working with the intricacies of GPCR modulators. Watch the recent anti-obesity therapeutics webinar: https://lnkd.in/ggyErJG9

🚀 We’re excited to announce our participation at MCS2024 – The 41st Medicinal Chemistry Symposium in Kyoto, Japan, from November 20-22! You can find us at Cosmo Bio’s booth No. 24, where we’ll be discussing Integrated Drug Discovery Solutions that support chemists & biologists from concept to candidate. 🎙️ Luncheon Seminar with Olivier Mirguet, PhD Take advantage of this opportunity to dive into the future of drug discovery! • Session: Luncheon Seminar 1 (LS-4) • Topic: AI-Enhanced Identification and Full Characterization of PIM Degraders • Date & Room: November 20, West 3F Conference Room No. 2 Come explore how you can accelerate your projects with Eurofins Discovery’s interdisciplinary approach. See you at Kyoto Terrsa! #EurofinsDiscovery #MCS2024 #Kyoto #MedicinalChemistry #DrugDiscovery

When Eurofins Discovery launched our first dedicated services to support Biotherapeutic drug discovery and development, we believed we could help our partners free their biologics drug discovery from the inhibition of limited resources and expertise. To fulfill this promise, we are adding key scientific and commercial team members while incorporating all modalities in an ever-evolving drug discovery landscape. With these new resources at your disposal, you benefit by collaborating with our seasoned team of PhD-level scientists to navigate the challenges toward regulatory approval: ✔ Access to the right state-of-the-art technologies ✔ Insights from custom assay readouts ✔ Extensive laboratory network to streamline your research Our team is excited to support you! Please reach out to schedule your consultation: https://lnkd.in/gnZ5bmF9 #Biologics #Biotherapeutics #DrugDiscovery #EurofinsDiscovery

🌟 Strengthening Ties: Cosmo Bio Visits Eurofins Discovery in Taipei! 🌟 We were delighted to host our distinguished partners in Japan - Cosmo Bio - at the Eurofins Discovery Taipei site! 💡 During the visit, we engaged in meaningful discussions that highlighted Eurofins Discovery's comprehensive capabilities and the latest insights from Cosmo Bio. We explored several promising opportunities for collaboration, aimed at enhancing customer service quality and efficiency. These initiatives are key to driving the pharmaceutical industry in Japan with solid support from Eurofins Discovery. 🤝 Meeting with our partners face-to-face deepens our understanding and paves the way for pioneering collaborations that promise significant advantages for our clients. We are excited to continue building this strong foundation and enhance our client support through these strategic partnerships. #EurofinsDiscovery #Partner #DrugDiscovery #CosmoBio #Pharmaceuticals

📣 The move into our new Fremont laboratory for LeadHunter Services is now complete! The new address is: 47100 Bayside Pkwy Fremont, CA 94538 USA This new facility will enable: ✔ An optimized laboratory design to support future long-term growth and capabilities. ✔ Environmentally sustainable operations with green energy. The Eurofins Discovery Client Services team is here to help with any questions or concerns about the new facility at ClientServices.SCal@discovery.eurofinsus.com.

The growing adoption of generative artificial intelligence (AI) in the drug discovery process promises to revolutionize the identification of novel drugs and to shorten development time.  Efficiently translate AI-mediated discoveries into safe & impactful drugs with our comprehensive Integrated Drug Discovery (IDD) solutions. ✔ Extensive Assay Portfolio: An industry-leading breadth of target-based and translational assays, with new panels on helicases, SH2 domains, and obesity targets. ✔ Experience: With the IDD team, you work directly with scientists with years of discovery experience. They collaboratively guide the program, design necessary assays & services, and tap into scientific subject matter experts. ✔ Innovative AI Solutions: Complement your approaches with Eurofins’ DiscoveryAI & access cutting-edge tools. Join the companies using Eurofins Discovery as their trusted partner for end-to-end drug development services, from target validation to IND-enabling studies. https://lnkd.in/ge3DiVdQ

Did you miss our recent webinar, “Accelerating Drug Discovery with Synthetic Chemistry Advances”? Or did you attend and want to revisit key insights? Great news—the recording is now available! Presented by Matthew Horwitz, this webinar highlights the latest approaches in drug discovery, with a focus on small molecules and emerging modalities like proteolysis-targeting chimeras (PROTACs) and antibody-drug conjugates (ADCs). Access the webinar recording: https://lnkd.in/dUH6Pxec At Eurofins Discovery, we cover the entire drug discovery workflow with over 10,000 off-the-shelf assays, from chemistry capabilities to biology services. Learn more and connect with our experts: https://lnkd.in/ehhRvvxc #DrugDiscovery #Chemistry #SyntheticChemistry 

🚀 Reach Next-Level Drug Discovery with DiscoveryAI SAFIRE! Ready to transform your drug discovery process? Our cutting-edge SAFIRE technology, powered by AI and high-quality Eurofins Discovery data, is here to revolutionize how you approach drug development. 🔗 Watch the Video: Get an inside look at how SAFIRE can elevate your drug discovery process. https://lnkd.in/g-vFtfmU Start harnessing the power of SAFIRE today and make informed decisions with confidence! #DrugDiscovery #AI #Pharma #Innovation #MachineLearning

🚀 Exciting developments at Eurofins Discovery Taiwan! The team recently had the pleasure of hosting Dr. Alastair J. King, Head of Biology at Eurofins Discovery, from the St. Charles site in the U.S. 💡 Dr. King shared valuable insights, including a successful case of using BioMAP® and OncoPanel® in oncology drug discovery, providing the Taiwan team with key takeaways. His strategies inspired new ideas on aligning our unique service portfolio to serve clients better globally. 🌍 Cross-site visits like this are invaluable, strengthening our teamwork and fueling innovation. We look forward to more collaboration across the Eurofins Discovery network! #Eurofins #EurofinsAsia #EurofinsDiscovery #Oncopanel #BioMAP #Collaboration

Exciting news! We are expanding our Oncology portfolio. In our ongoing quest for innovation, coupled with always meeting our clients' needs as effectively as possible, we are investing in our oncology capabilities. We recently expanded our SH2scan™ platform, adding new SH2 domain assays for proteins in a variety of classes including E3 ligases, adaptor proteins, phosphatases, GTPase-activating proteins, and phospholipases for a comprehensive SH2MAX panel that brings this “undruggable” target class within therapeutic reach. This panel uses the same proprietary binding assay technology as our KINOMEscan platform. Download our flyer now to explore new approaches in drug discovery targeting SH2 domains and see our remaining 2024 screening slots to check if your molecules are active - only 3 slots left before the end of this year. Download: https://lnkd.in/gQv5_-cP #Eurofins #Oncology #DrugDiscovery